ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "KIR, HLA - C, & Rituximab"
Episode Synopsis
This week we hype the seemingly negative impact of KIR2DS1/HLA-C2/C2 genotype on rituximab benefit in aggressive lymphomas.
We also cover updates in breast cancer (pembrolizumab in TNBC; AIs in pre-menopausal women) and cervical cancer (cemiplimab).
KIR & Rituximab: https://doi.org/10.1016/S2352-3026(21)00369-0
Keynote-522 Update w/ EFS analysis: https://www.nejm.org/doi/full/10.1056/NEJMoa2112651
Premenopausal Breast Cancer AIs vs. Tam Meta-Analysis: https://doi.org/10.1016/S1470-2045(21)00758-0
Cemiplimab in cervical cancer: https://www.nejm.org/doi/full/10.1056/NEJMoa2112187
We also cover updates in breast cancer (pembrolizumab in TNBC; AIs in pre-menopausal women) and cervical cancer (cemiplimab).
KIR & Rituximab: https://doi.org/10.1016/S2352-3026(21)00369-0
Keynote-522 Update w/ EFS analysis: https://www.nejm.org/doi/full/10.1056/NEJMoa2112651
Premenopausal Breast Cancer AIs vs. Tam Meta-Analysis: https://doi.org/10.1016/S1470-2045(21)00758-0
Cemiplimab in cervical cancer: https://www.nejm.org/doi/full/10.1056/NEJMoa2112187
More episodes of the podcast OncoPharm
Bladder Cancer Updates & SC Amivantamab
18/12/2025
ASH 2025
11/12/2025
DPYD Deficiency Testing
04/12/2025
Cornucopia of Autumn Updates
26/11/2025
PGYNone: Dandelion Effect
20/11/2025
PGY1 Pathway: Road Trip!
13/11/2025
PGY2 Pathway: A Planned City
06/11/2025
Tale from the Crypt: Belantamab Mafodotin
30/10/2025
ESMO 2025
23/10/2025
IL-2
16/10/2025
In God we trust